These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21427105)

  • 1. Discrepancies in fluoroquinolone clinical categories between the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI for Escherichia coli harbouring qnr genes and mutations in gyrA and parC.
    Rodríguez-Martínez JM; Briales A; Velasco C; Díaz de Alba P; Martínez-Martínez L; Pascual A
    J Antimicrob Chemother; 2011 Jun; 66(6):1405-7. PubMed ID: 21427105
    [No Abstract]   [Full Text] [Related]  

  • 2. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
    Moon DC; Seol SY; Gurung M; Jin JS; Choi CH; Kim J; Lee YC; Cho DT; Lee JC
    Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diverse phenotypic and genotypic characterization among clinical Klebsiella pneumoniae and Escherichia coli isolates carrying plasmid-mediated quinolone resistance determinants.
    Yang J; Luo Y; Cui S; Wang W; Han L
    Microb Drug Resist; 2011 Sep; 17(3):363-7. PubMed ID: 21563956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
    Lee YJ; Cho JK; Kim KS; Tak RB; Kim AR; Kim JW; Im SK; Kim BH
    J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.
    Shigemura K; Tanaka K; Yamamichi F; Shirakawa T; Miyake H; Fujisawa M
    Int J Antimicrob Agents; 2012 Dec; 40(6):516-20. PubMed ID: 23068598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fluoroquinolone resistance mutations in topoisomerase genes of Salmonella typhimurium isolates].
    Guo Y; Pei X; Liu X
    Wei Sheng Yan Jiu; 2004 Sep; 33(5):591-4. PubMed ID: 15612489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant-prevention concentrations of enrofloxacin for Escherichia coli isolates from chickens.
    Li Q; Bi X; Diao Y; Deng X
    Am J Vet Res; 2007 Aug; 68(8):812-5. PubMed ID: 17669019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance.
    Emrich NC; Heisig A; Stubbings W; Labischinski H; Heisig P
    J Antimicrob Chemother; 2010 Dec; 65(12):2530-3. PubMed ID: 20940181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative.
    Lautenbach E; Fishman NO; Metlay JP; Mao X; Bilker WB; Tolomeo P; Nachamkin I
    J Infect Dis; 2006 Jul; 194(1):79-85. PubMed ID: 16741885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolone resistance and molecular characterization of gyrA and parC quinolone resistance-determining regions in Escherichia coli isolated from poultry.
    Vanni M; Meucci V; Tognetti R; Cagnardi P; Montesissa C; Piccirillo A; Rossi AM; Di Bello D; Intorre L
    Poult Sci; 2014 Apr; 93(4):856-63. PubMed ID: 24706962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-level resistance to fluoroquinolones linked to mutations in gyrA, parC, and parE in Salmonella enterica serovar Schwarzengrund isolates from humans in Taiwan.
    Baucheron S; Chaslus-Dancla E; Cloeckaert A; Chiu CH; Butaye P
    Antimicrob Agents Chemother; 2005 Feb; 49(2):862-3. PubMed ID: 15673791
    [No Abstract]   [Full Text] [Related]  

  • 12. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in clinical strains of fluoroquinolone-resistant Shigella in Anhui, China.
    Hu LF; Li JB; Ye Y; Li X
    J Microbiol; 2007 Apr; 45(2):168-70. PubMed ID: 17483803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid and sensitive detection of fluoroquinolone-resistant Escherichia coli from urine samples using a genotyping DNA microarray.
    Yu X; Susa M; Weile J; Knabbe C; Schmid RD; Bachmann TT
    Int J Med Microbiol; 2007 Oct; 297(6):417-29. PubMed ID: 17482874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
    Briales A; Rodríguez-Martínez JM; Velasco C; Díaz de Alba P; Domínguez-Herrera J; Pachón J; Pascual A
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1266-9. PubMed ID: 21173174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid detection of gyrA and parC mutations in fluoroquinolone-resistant Neisseria gonorrhoeae by denaturing high-performance liquid chromatography.
    Shigemura K; Shirakawa T; Okada H; Tanaka K; Udaka T; Kamidono S; Arakawa S; Gotoh A
    J Microbiol Methods; 2004 Dec; 59(3):415-21. PubMed ID: 15488283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
    Zhao X; Quinn B; Kerns R; Drlica K
    J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-beta-lactamase-producing Escherichia coli isolates.
    Sorlozano A; Gutierrez J; Jimenez A; de Dios Luna J; Martínez JL
    J Clin Microbiol; 2007 Aug; 45(8):2740-2. PubMed ID: 17567787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors and mechanisms of fluoroquinolone resistance in 156 Escherichia coli strains clinically isolated from urinary tract infections.
    Yasufuku T; Shigemura K; Shirakawa T; Nakano Y; Tanaka K; Arakawa S; Kinoshita S; Nishimura K; Kawabata M; Fujisawa M
    Scand J Infect Dis; 2011 Feb; 43(2):83-8. PubMed ID: 20942776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of fluoroquinolone-resistant Shigella flexneri in Hangzhou area of China.
    Pu XY; Pan JC; Wang HQ; Zhang W; Huang ZC; Gu YM
    J Antimicrob Chemother; 2009 May; 63(5):917-20. PubMed ID: 19297378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.